127.83
  Price0.44%   +0.56
(After Hours: 125.53 -2.30 -1.80%)
Jun-16-21 11:25AM CRISPR (CRSP) Inks Deal for Gene Therapies in Neurological DiseasesZacks Investment Research
Jun-15-21 06:55AM Can Vertex Pharmaceuticals Recover From Its Latest Setback?The Motley Fool
05:40AM Is It Too Late to Buy Vertex Pharmaceuticals Stock?The Motley Fool
Jun-14-21 10:50AM CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 DataZacks Investment Research
10:47AM Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2021Benzinga
Jun-14-21 09:31AM 10 Biggest Price Target Changes For MondayBenzinga
Jun-08-21 05:50AM CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research
Jun-07-21 07:11AM What's the Best Way to Invest in Genetics Stocks?The Motley Fool
Jun-06-21 12:16PM How Much Will the Nkarta Deal Help CRISPR Therapeutics?The Motley Fool
Jun-04-21 07:21AM 1 Genetics Stock to Put on Your RadarThe Motley Fool
Jun-03-21 10:20AM Battle of the $54 Billion Assets: Buy This, Not DogecoinThe Motley Fool
Jun-02-21 05:50AM CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research
May-27-21 11:31AM CRISPR Therapeutics AG (CRSP) Down 12.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research
May-26-21 06:10AM Don't Wait For a Market Crash: These 2 Top Stocks Are On SaleThe Motley Fool
06:05AM 4 Unstoppable Healthcare Stocks to Buy on the DipThe Motley Fool
May-25-21 01:12AM Crispr Therapeutics: Pullback Has Created OpportunitySeeking Alpha
May-22-21 06:25AM Is Vertex Pharmaceuticals a Buy?The Motley Fool
May-17-21 06:15AM Earnings Roundup: General Motors, Editas Medicine, Activision Blizzard, Match GroupThe Motley Fool
May-13-21 05:31AM 3 Mistakes to Avoid When Investing in Biotech StocksThe Motley Fool
May-12-21 06:14AM 3 Healthcare Stocks That Might Soar if Biden Gets This Part of His Budget ApprovedThe Motley Fool
May-11-21 06:40AM Avoid the Dogecoin Crash by Buying These 2 Growth Stocks InsteadThe Motley Fool
May-07-21 11:38AM Nkarta, CRISPR Join Forces On CAR-NK Development For CancerBenzinga
06:40AM With 1 Cure Behind It, This Breakthrough Biotech Takes Aim at a Bigger MarketMotley Fool
May-06-21 04:01AM CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for CancerGlobeNewswire
May-04-21 06:00AM This Bold Statement by the Vertex CEO Means a New Blockbuster May be Here SoonMotley Fool
May-01-21 06:10AM Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock?Motley Fool
Apr-29-21 10:01AM Vertex Pharmaceuticals Inc (VRTX) Q1 2021 Earnings Call TranscriptMotley Fool
04:17AM Best Biotech Stocks & ETFs for mRNA, Gene EditingZacks
Apr-29-21 08:30AM CRISPR Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
03:26AM Shareholders Are Thrilled That The CRISPR Therapeutics (NASDAQ:CRSP) Share Price Increased 179%Simply Wall St.
Apr-28-21 04:01AM CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual MeetingGlobeNewswire
12:18PM Biotech Stock Roundup: BIIB, AMGN's Q1 Earnings Updates & Other Pipeline NewsZacks
Apr-28-21 09:56AM CRISPR Therapeutics (CRSP) Q1 Earnings Miss, Revenues Rise Y/YZacks
Apr-27-21 05:15AM CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue EstimatesZacks
04:01AM CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsGlobeNewswire
Apr-27-21 01:53AM Crispr Therapeutics Gets Relative Strength Rating UpgradeInvestor's Business Daily
Apr-26-21 02:47AM Skyworks Lifts Nasdaq Ahead of Earnings; CRISPR Keeps Moving ForwardMotley Fool
08:30AM Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta ThalassemiaGlobeNewswire
Apr-23-21 05:50AM CRISPR Therapeutics AG (CRSP) Gains But Lags Market: What You Should KnowZacks
08:09AM Is a Beat in Store for CRISPR (CRSP) This Earnings Season?Zacks
Apr-23-21 06:35AM 2 Unstoppable Cathie Wood Stocks That Could Make You RichMotley Fool
Apr-21-21 02:54AM Biotech Stock Roundup: BMYs Opdivo Gets FDA Nod for Gastric Cancer & Other UpdatesZacks
08:55AM Vertex (VRTX) Ups Investment in CRISPR Gene Therapy PartnershipZacks
Apr-21-21 08:10AM CRISPR Therapeutics Is Upgraded After $900 Million DealBarrons.com
Apr-20-21 04:29AM Vertex Pharmaceuticals Raises Bet on CRISPR TherapeuticsMotley Fool
12:31PM Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out forZacks
Apr-20-21 10:20AM Vertex Is Buying Majority Rights to Gene-Editing Therapy From CRISPR TherapeuticsBarrons.com
07:15AM Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta ThalassemiaGlobeNewswire
Apr-16-21 03:51AM CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks TodayInvestorPlace
Apr-10-21 08:31AM CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell FunctionGlobeNewswire
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:    |  Volume (24h):